相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
Liu Weiping et al.
CANCER MEDICINE (2020)
Mortality of lymphoma and myeloma in China, 2004-2017: an observational study
Weiping Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)
Flavia Salvi et al.
LEUKEMIA & LYMPHOMA (2019)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2019)
Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016
Weiping Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors
Simone de Vries et al.
BRITISH JOURNAL OF CANCER (2018)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
C. Buske et al.
ANNALS OF ONCOLOGY (2018)
Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors
Talya Salz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Improved survival time trends in Hodgkin's lymphoma
Matthew Koshy et al.
CANCER MEDICINE (2016)
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
Anne-Sophie Michallet et al.
HAEMATOLOGICA (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
Anne-Sophie Michallet et al.
HAEMATOLOGICA (2015)
Cardiovascular Disease After Hodgkin Lymphoma Treatment 40-Year Disease Risk
Frederika A. van Nimwegen et al.
JAMA INTERNAL MEDICINE (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group
Diana Wongso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
